Demand has surged for good manufacturing practice (GMP)–grade plasmid DNA (pDNA) used in late-phase clinical trials and commercial manufacturing due to the starting material’s critical role in producing nextgeneration therapies. The same is true for minicircle DNA (mcDNA) — supercoiled-DNA vectors that can be obtained from plasmids through cutting-edge in vivo recombination techniques. Because mcDNA lacks plasmid backbone sequences and contains primarily active genes, it can provide enhanced transgene expression with greater persistence than conventional plasmids can. Considering the biopharmaceutical industry’s great need for both pDNA and mcDNA, tools supporting fast-growing, high-yielding microbial cultures are becoming increasingly important.
Register or Login and hit Download to get the full article. biotechnology model
Cold chain infrastructure hangs over bird flu vaccine prep
Vaccine skeptic Kennedy advances in bid to lead HHS
Lantheus goes Evergreen in a $250m upfront deal
Cell mates: SCTbio, CCRM Nordic amp up cell therapy production
benchtop fermenter Copyright © 2025 Informa Connect Limited. Registered in England & Wales with number 01835199, registered office 5 Howick Place, London, SW1P 1WG.